Lung Cancer Dispatch
Follow
Find tag "radiation"
3.6K views | +1 today
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Scooped by Cancer Commons
Scoop.it!

Thoracic RT Yields Improved Survival in Extensive-Stage SCLC

Thoracic RT Yields Improved Survival in Extensive-Stage SCLC | Lung Cancer Dispatch | Scoop.it

"Thoracic radiotherapy along with prophylactic cranial irradiation (PCI) significantly prolonged progression-free and overall survival in patients with extensive-stage small-cell lung cancer, according to results of a new study presented at ASCO.


"Ben Slotman, MD, PhD, of VU University Medical Center in Amsterdam, presented the study and said that previous work had shown that PCI could improve both symptomatic brain metastases and overall survival at 1 year. 'In that study, we also noticed that the vast majority of patients after chemotherapy had intrathoracic disease' and intrathoracic progression, he said, which was the impetus for the new study using thoracic radiotherapy."


Editor's note: To learn more about new prospects for treating small cell lung cancer (SCLC), see our two-part blog feature on the topic.

Cancer Commons's insight:

Cancer Network  |  Jun 5, 2014

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

ASCO: Chemotherapy Key Part of Curative Lung Cancer Therapies

ASCO: Chemotherapy Key Part of Curative Lung Cancer Therapies | Lung Cancer Dispatch | Scoop.it

"Cancer Network: Thank you for speaking with us today, Dr. Kris. First, can you tell us why this is an important topic for an education session? Is there a debate of the use of chemotherapy in treating lung cancer?


"Dr. Kris: I wouldn’t quite say that there is a debate, but there is an impression that the therapy of lung cancers has switched to targeted therapies or immune therapies. Looking at the ASCO abstracts this year that would be an easy conclusion to draw. But there is an indisputable fact that no matter what target you can identify in a patient’s tumor, be it PD-L1 or a BRAF mutation, at some point in a patient’s illness they will be receiving chemotherapy. As we look at entire care of people with lung cancer it is very important to remember that virtually every single one will receive chemotherapy, and that we need to pay attention to choosing the best chemotherapy. We also need to think about doing research in chemotherapy. Clearly, we can do a better job, and we need more research to find the best drugs. Also, we need to find a way to use them with our targeted therapies."


Editor's note: Targeted therapies and immunotherapies are all the rage now in cancer treatment. But there are still important roles for chemotherapy. This article gives a great overview of recent advancements in the use of chemotherapy in lung cancer treatment, and why we need further research to refine and improve the benefits of chemotherapy.

Cancer Commons's insight:

Cancer Network  |  May 29, 2014

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

Gene May Predict if Further Cancer Treatments are Needed

Gene May Predict if Further Cancer Treatments are Needed | Lung Cancer Dispatch | Scoop.it

"A new predictive tool that could help patients with breast cancer and certain lung cancers decide whether follow-up treatments are likely to help is being developed by researchers. The findings offer insight into helping patients assess treatment risk. Radiation therapy and chemotherapy that can destroy tumors also can damage surrounding healthy tissue. So with an appropriate test, patients could avoid getting additional radiation or chemotherapy treatment they may not need."


Editor's note: This study was performed in mice, so it will be several years before patients can benefit from it. However, doctors are already using molecular testing to guide treatment decisions, often for patients with advanced lung cancer. For early-stage patients, the Pervenio test can help determine whether lung cancer is likely to return after surgery, which can let doctors know to consider preventive ("adjuvant") treatments.

Cancer Commons's insight:

ScienceDaily  |  Mar 28, 2014

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

Concomitant Boost Thoracic Radiation Plus Chemotherapy Benefited NSCLC Patients

Concomitant Boost Thoracic Radiation Plus Chemotherapy Benefited NSCLC Patients | Lung Cancer Dispatch | Scoop.it

"A combination of concomitant boost thoracic radiation plus systemic chemotherapy appeared safe and effective among patients with locally advanced non–small cell lung cancer, according to phase 2 study results.


"Researchers evaluated accelerated hyperfractionation with concomitant boost thoracic radiation for 20 working days in doses of 64 Gy to the gross tumor volume, and 40 Gy to the elective clinical target volume. Patients also received cisplatin on day 1 and vinorelbine on days 1 and 8, with a 3-week interval."


Editor's Note: This story is about the results of a clinical trial. Clinical trials are research studies with volunteer patients. Many people who enroll in trials receive experimental treatments that they would not otherwise be able to have. Read more about how to see if a clinical trial is right for you: http://www.cancercommons.org/patients-caregivers/lung-cancer/the-basics-lung-cancer/#clinical

Cancer Commons's insight:

Healio  |  Mar 11, 2014

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

Tracer Could Indicate Radiation Benefit to Patient

Tracer Could Indicate Radiation Benefit to Patient | Lung Cancer Dispatch | Scoop.it

"A world-first radiotherapy treatment trial by University of WA researchers could have a major impact on the quality of life for mesothelioma patients.


"Funded by an almost $100,000 Cancer Council WA grant, the research team is exploring why some patients respond to radiotherapy treatment while others don't, as well as developing tests to predict whether patients will respond to avoid people being treated unnecessarily."

Cancer Commons's insight:

Medical Xpress  |  Jun 3, 2014

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

Radiotherapy: Novel Lung Cancer Treatment Meets with Success

Radiotherapy: Novel Lung Cancer Treatment Meets with Success | Lung Cancer Dispatch | Scoop.it

"An old idea of retreating lung tumors with radiation is new again, especially with the technological advances seen in radiation oncology over the last decade. 'One of the toughest challenges of lung cancer is what to do for patients when the cancer comes back in an area that’s been treated previously with radiation treatment,' said the lead author. 'With some of the technological advances in radiation treatments that have occurred in the last five to 10 years, we’re beginning to re-look at the issue and ask – can we target the radiation precisely enough and with a high enough dose to knock the cancer back?'

Cancer Commons's insight:

ScienceDaily  |  May 8, 2014

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

Potential Lung Cancer Vaccine Shows Renewed Promise

Potential Lung Cancer Vaccine Shows Renewed Promise | Lung Cancer Dispatch | Scoop.it

"Researchers at UC Davis have found that the investigational cancer vaccine tecemotide, when administered with the chemotherapeutic cisplatin, boosted immune response and reduced the number of tumors in mice with lung cancer. The study also found that radiation treatments did not significantly impair the immune response. The paper was published on March 10 in the journal Cancer Immunology Research, an American Association for Cancer Research (AACR) publication.


"Though tecemotide, also known as Stimuvax, has shown great potential at times, the recent Phase III trial found no overall survival benefit for patients with non-small cell lung cancer (NSCLC). However, further analysis showed one group of patients, who received concurrent chemotherapy and radiation followed by tecemotide, did benefit from the vaccine. As a result, tecemotide's manufacturer, Merck KGaA, is sponsoring additional post-clinical animal and human studies, so far with good results."


Editor's note: Cancer vaccines are meant to stimulate the immune system to fight cancer. Stimuvax is a cancer vaccine that was found to have no overall survival benefit for patients in a recent clinical trial. But closer analysis of the trial data and the mouse study mentioned above have raised hopes that the vaccine might work with some combination of chemo and radiation treatment.

Cancer Commons's insight:

Medical Xpress  |  Mar 20, 2014

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

New Treatment Proposed to Prevent Devastating Intestinal Inflammation in Cancer Patients

New Treatment Proposed to Prevent Devastating Intestinal Inflammation in Cancer Patients | Lung Cancer Dispatch | Scoop.it

"Experimental work pointing to a therapy for alleviating mucositis -- a common, severe side effect of chemotherapy and irradiation of cancer patients or patients prepared for bone marrow transplantation – has been achieved by an international team of researchers. Mucositis is a strong inflammatory reaction of the mucosal lining of the digestive system, particularly the gut. Mucositis is often a major reason for premature suspension of anti-cancer therapy. As of today, there has been no effective means of preventing mucositis or its treatment."

Cancer Commons's insight:

ScienceDaily  |  Feb 18, 2014 

more...
Cancer Commons's curator insight, February 28, 1:51 PM

ScienceDaily  |  Feb 18, 2014 

Cancer Commons's curator insight, February 28, 1:51 PM

ScienceDaily  |  Feb 18, 2014